Novartis Stock Surges After Oral Multiple Sclerosis Treatment Meets Clinical Trial Objectives

Pharmaceutical giant Novartis saw its shares climb after announcing that its experimental oral pill successfully achieved primary endpoints in trials for treating multiple sclerosis.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

la-vanguardiaSpanish1d ago

Luz verde al Estatuto Marco de los trabajadores de la sanidad, con el rechazo de los médicos

El proyecto de Mónica García será remitido a las Cortes, donde no tiene garantizada la mayoría necesaria

Read full article →

Novartis Stock Surges After Oral Multiple Sclerosis Treatment Meets Clinical Trial Objectives

Sources

Luz verde al Estatuto Marco de los trabajadores de la sanidad, con el rechazo de los médicos

Related Stories

Study suggests widely used sweetener may have serious health risks

Lionel Richie Hospitalized in Intensive Care Following Concert Appearance

Measles Outbreak Death Toll in Bangladesh Surpasses 980

Mbappé-Backed Health Startup Alan Expands Into West Africa